Penn spinout Carisma Therapeutics, co-founded by Dr. Saar Gill, which focuses on creating life-changing cellular therapies for patients with cancer and other serious disorders, announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors. This trial aims to evaluate the safety, tolerability and manufacturing feasibility of CT-0525, with expectations of reporting initial data by the end of 2024.
Additionally, Carisma recently named Eugene P. Kennedy, M.D., F.A.C.S., as its new Chief Medical Officer. Kennedy, who has over 15 years of experience in clinical and industry roles in oncology and immuno-oncology, will oversee Carisma’s clinical development, regulatory and medical affairs. Read more here: